Charles Schwab Investment Management Inc. Has $23.30 Million Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Charles Schwab Investment Management Inc. boosted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 7.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 648,652 shares of the company’s stock after acquiring an additional 47,590 shares during the period. Charles Schwab Investment Management Inc. owned 0.65% of Dyne Therapeutics worth $23,300,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. AQR Capital Management LLC lifted its stake in shares of Dyne Therapeutics by 4.3% in the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after buying an additional 352 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Dyne Therapeutics by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after purchasing an additional 709 shares during the last quarter. KBC Group NV raised its stake in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after acquiring an additional 751 shares during the last quarter. Finally, Amalgamated Bank boosted its position in Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after acquiring an additional 796 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Down 5.8 %

Dyne Therapeutics stock opened at $27.74 on Friday. The stock has a market cap of $2.82 billion, a P/E ratio of -8.03 and a beta of 1.09. Dyne Therapeutics, Inc. has a 12 month low of $10.33 and a 12 month high of $47.45. The company’s fifty day simple moving average is $31.34 and its 200-day simple moving average is $35.44.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DYN has been the topic of several analyst reports. Oppenheimer reiterated an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics in a report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price target for the company. Guggenheim boosted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Finally, Chardan Capital reiterated a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $50.82.

Insider Buying and Selling at Dyne Therapeutics

In related news, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the sale, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. This trade represents a 6.38 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Carlo Incerti sold 16,500 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $28.73, for a total value of $474,045.00. The disclosure for this sale can be found here. Insiders have sold 176,257 shares of company stock valued at $6,193,718 in the last 90 days. 20.77% of the stock is currently owned by company insiders.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.